AMGN insider files Form 144 to sell 1,267 shares on 08/20/2025 via Raymond James

Rhea-AI Filing Summary

Amgen Inc. (AMGN) Form 144 notice reports a proposed sale of 1,267 shares of common stock through Raymond James & Associates on 08/20/2025 with an aggregate market value of $372,908.81. The shares were acquired from the issuer on 03/18/2024 via RSE/DEU grants and paid in cash. The filing lists 538,360,000 shares outstanding. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Clear disclosure of proposed sale details including broker, number of shares, aggregate value, and sale date
• Securities were acquired via issuer grants (RSE/DEU) and paid in cash, indicating the shares originated from compensation
• No sales in past three months reported for the selling person

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider proposes a modest sale (1,267 shares) from grant-originated holdings; impact appears immaterial relative to outstanding float.

The filing documents a routine Rule 144 sale linked to equity grants received 03/18/2024 and to be executed through Raymond James on 08/20/2025. At an aggregate value of $372,908.81 against 538.36 million shares outstanding, the transaction size is immaterial to capital structure and does not indicate material dilution or company-level financial change. The absence of other sales in the prior three months suggests this is an isolated planned disposition rather than a pattern of insider selling.

Corporate Governance Expert

TL;DR: The notice is a compliant disclosure of an insider sale from equity awards; governance implications are minor and procedural.

The Form 144 provides required transparency for a proposed transfer of shares acquired via RSE/DEU grants. The seller certifies no undisclosed material adverse information. From a governance perspective, this is standard reporting of personal liquidity by a stakeholder and does not, on its face, raise red flags about management conduct or disclosure practices. Documentation appears complete for the required elements included in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	1267	372908.81	538360000	08/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/18/2024	RSE/DEU Grants	Issuer			1267	03/18/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being sold in the AMGN Form 144 filing?

The filing reports a proposed sale of 1,267 shares of Amgen common stock.

When will the AMGN shares be sold and through which broker?

The sale is scheduled for 08/20/2025 through Raymond James & Associates.

How were the shares acquired that are being sold?

The shares were acquired on 03/18/2024 via RSE/DEU grants from the issuer and paid in cash.

What is the aggregate market value and outstanding shares reported?

Aggregate market value is $372,908.81 and the filing lists 538,360,000 shares outstanding.

Has the seller reported other sales in the past three months?

The filing states Nothing to Report for securities sold during the past three months.